The health and safety of the PCPV summit registrants is our number one priority. Due to the uncertainty of the impact of COVID-19, we have made the difficult decision to postpone the PCPV Summit to Sept. 14–15th 2022. In the interim, we will be launching a speaker series discussing PV challenges with PCPV Summit speakers and PCPV Board members. Be sure to click Stay Informed below for more updates about the speaker series and PCPV Summit 2022.

Speakers Series

Speakers Series

DILI Pearls: CIOMS DILI WG: A Conversation with Dr. Javier Waksman

Dr. Javier Waksman, the Vice-President of Drug Safety at Sangamo Therapeutics speaks with Bethany Van Veen, CEO and founder of Perspective Pharmacovigilance, about the recent Drug Induced Liver Injury (DILI) CIOMS Working Group publication. Dr. Waksman offers practical solutions for the identification, characterization, and management of DILI during development, as well as after product launch. He describes the CIOMS Working Group’s overall objectives and what challenges they faced while developing the publication. Dr. Waksman also discusses the advancements he believes are on the horizon regarding DILI from a clinical, pharmacovigilance, and regulatory standpoint.

Bethany Van Veen

CEO and Founder
Perspective Pharmacovigilance, Inc.

Dr. Javier Waksman

Vice President, Head of Drug Safety
Sangamo Therapeutics, Inc.

Navigating an MHRA GCP Reference Safety Information (RSI) Office Based Inspection (OBI): An Interview with Evan Blander

Bethany Van Veen, CEO and founder of Perspective Pharmacovigilance, discusses Exelixis’ first ever virtual MHRA GCP inspection with Evan Blander, Vice-President of Drug Safety at Exelixis. Evan describes the unique challenges to this new virtual inspection concept; everything from building rapport with inspectors to modifying traditional inspection SOPs to asking the question, ‘does a War Room still make sense when everyone is remote?’ Evan offers practical advice to other companies who may be preparing for an upcoming inspection and reflects on what he and his team may have done differently to make the inspection process more seamless and effective.

Bethany Van Veen

CEO and Founder
Perspective Pharmacovigilance, Inc.

Evan Blander

Vice President, Drug Safety
Exelixis, Inc.

Coming soon
DILI Pearls: CIOMS DILI WG: A Conversation with Dr. Javier Waksman

Dr. Javier Waksman, the Vice-President of Drug Safety at Sangamo Therapeutics speaks with Bethany Van Veen, CEO and founder of Perspective Pharmacovigilance, about the recent Drug Induced Liver Injury (DILI) CIOMS Working Group publication. Dr. Waksman offers practical solutions for the identification, characterization, and management of DILI during development, as well as after product launch. He describes the CIOMS Working Group’s overall objectives and what challenges they faced while developing the publication. Dr. Waksman also discusses the advancements he believes are on the horizon regarding DILI from a clinical, pharmacovigilance, and regulatory standpoint.

Dr. Javier Waksman

Vice President, Head of Drug Safety
Sangamo Therapeutics, Inc.

Bethany Van Veen

CEO and Founder
Perspective Pharmacovigilance, Inc.

Navigating an MHRA GCP Reference Safety Information (RSI) Office Based Inspection (OBI): An Interview with Evan Blander

Bethany Van Veen, CEO and founder of Perspective Pharmacovigilance, discusses Exelixis’ first ever virtual MHRA GCP inspection with Evan Blander, Vice-President of Drug Safety at Exelixis. Evan describes the unique challenges to this new virtual inspection concept; everything from building rapport with inspectors to modifying traditional inspection SOPs to asking the question, ‘does a War Room still make sense when everyone is remote?’ Evan offers practical advice to other companies who may be preparing for an upcoming inspection and reflects on what he and his team may have done differently to make the inspection process more seamless and effective.

Evan Blander

Vice President, Drug Safety
Exelixis, Inc.

Bethany Van Veen

CEO and Founder
Perspective Pharmacovigilance, Inc.

Coming soon

Focusing on real-world solutions to everyday pharmacovigilance challenges.

September 14–15, 2022

Hilton San Francisco Airport Bayfront
600 Airport Blvd.
Burlingame, CA 94010

Hosted by Perspective Pharmacovigilance.
To learn more, click here:

Focusing on real-world solutions to everyday pharmacovigilance challenges.

September 14–15, 2022

Hilton San Francisco Airport Bayfront
600 Airport Blvd.
Burlingame, CA 94010

Hosted by Perspective Pharmacovigilance.
To learn more, click here:

Focusing on real-world solutions to everyday pharmacovigilance challenges.

September 14–15, 2022

Hilton San Francisco Airport Bayfront
600 Airport Blvd.
Burlingame, CA 94010

Hosted by Perspective Pharmacovigilance.
To learn more, click here: